Spectral Med Inc (EDT.TO) is seeing a boost in its stock price, reflecting investor confidence and interest in the market.
In the latest trading session, Spectral Med Inc's stock rose by 1.49%, closing at CA$1.36. This increase comes as the company progresses with its clinical trials and regulatory preparations, hinting at a promising future for investors.
Advertisement
Spectral Med Inc
EDT.TO
EDT.TO
Spectral Med Inc
WealthAwesomeAdvertisement
Market cap
$407.85M
52W high
$1.84
52W low
$0.97
1W change
-1.42%
Beta
0.21
Analyst Price Targets
Based on analyst covering EDT
Wall Street analysts forecast EDT stock price to rise 126.6% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$3.15
+126.6% Upside
Current Price
C$1.39
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Advertisement
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on EDT's historical volatility
30-Day Vol
27.0%
Annualized
90-Day Vol
28.5%
Annualized
Trend (90d)
-6.0%
Annualized drift
90d Mean
C$1.36
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$1.38 | C$1.26 – C$1.51 |
| 60 trading days | C$1.37 | C$1.20 – C$1.56 |
| 90 trading days | C$1.36 | C$1.16 – C$1.60 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: For Canadian investors, this recent gain in Spectral Med Inc's stock may indicate growing confidence in the company's future, especially as it makes strides in important clinical trials and regulatory processes.
Spectral Med Inc Stock Up 1.49% in One Day
With a market cap of CA$393.18 million, Spectral Med's recent stock performance shows increasing interest in its innovative medical solutions.
Bull case
The rise in Spectral Med's stock could be due to investor optimism about its Tigris trial and the potential FDA approval for its PMX product, which could lead to significant market opportunities.
Bear case
On the flip side, investors should stay cautious since the company has not yet turned a profit or paid dividends, and any delays in regulatory approvals could affect stock performance.
Recent Performance Overview
Advertisement
Spectral Med Inc's stock has increased by 1.49% in the last trading session, closing at CA$1.36. This rise is noteworthy given the company's market cap of CA$393.18 million, showing a healthy level of investor interest.
Factors Driving Investor Confidence
The recent gains are fueled by positive sentiment around the company's advancements in clinical trials, especially the Tigris trial. Investors are closely watching for updates on regulatory approvals that could greatly influence the company's future.
Looking Ahead
As Spectral Med Inc moves forward with its clinical trials and regulatory processes, investors should keep an eye on upcoming milestones. The company's ability to navigate these challenges will be key to maintaining its stock performance in the future. For more detailed insights, visit our Spectral Med Inc stock page.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
